Almirall deepens its dermatology dive with a $386M deal

Spanish drugmaker Almirall, moving on from its former focus on respiratory therapies, is beefing up its dermatology pipeline with a buyout of Switzerland's Poli Group. Under the deal, Almirall is acquiring all of Poli's shares for €365 million ($386 million), bringing in three clinical dermatology candidates and an R&D infrastructure the company said will help it generate more shots on goal in the field. Last year, Almirall signed away its respiratory business to AstraZeneca ($AZN) in a $2.1 billion deal, and the company has since been building up its capacity in treatments for skin disorders. More

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.